PMID: 12756022May 21, 2003Paper

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

European Journal of Haematology
Ching-Tien PengChang-Hai Tsai

Abstract

We conducted a prospective 3-yr clinical study comparing deferiprone (L1) with desferrioxamine (DFX). The therapeutic efficacy and potential side-effects on cardiac and/or hepatic systems of thalassemia patients were assessed by left ventricular ejection fraction, T2-weighted magnetic resonance imaging, and biochemical parameters. In both groups, levels of serum ferritin decreased significantly, and the hepatic function improved notably. Besides decrement of iron, no marked pathohistological changes were observed in the liver biopsies. These results indicated that for patients who failed to respond to DFX treatment, the use of L1 to remove excess iron deposition is recommended.

References

Jan 1, 1989·Clinical and Laboratory Haematology·A P FreemanI P Murray
Apr 1, 1989·Baillière's Clinical Haematology·J B Porter, E R Huehns
Jul 1, 1989·The American Journal of Medicine·D L JohnstonR Rokey
Sep 1, 1971·The American Journal of Clinical Nutrition·D M Livingston, W E Wacker
Apr 6, 1995·The New England Journal of Medicine·N F OlivieriG Koren
Sep 1, 1994·The New England Journal of Medicine·N F OlivieriA R Cohen
Jun 9, 1998·International Journal of Cardiac Imaging·S I MavrogeniD T Kremastinos
Aug 13, 1998·The New England Journal of Medicine·N F OlivieriK A Fleming
Nov 25, 1998·British Journal of Haematology·B WonkeA V Hoffbrand
Dec 2, 2000·Transfusion Science·G J KontoghiorghesA Kolnagou
Sep 13, 2001·European Journal of Haematology·A TaherF Mourad

❮ Previous
Next ❯

Citations

Jan 1, 2009·Mediterranean Journal of Hematology and Infectious Diseases·Athanasios Aessopos, Vasilios Berdoukas
Dec 1, 2009·Future Medicinal Chemistry·Heather C HatcherSuzy V Torti
Oct 20, 2004·British Journal of Haematology·Annita KolnagouGeorge J Kontoghiorghes
Mar 22, 2014·British Journal of Haematology·Yesim AydinokVip Viprakasit
Apr 1, 2011·Expert Opinion on Therapeutic Patents·Hossein HeliKhashayar Karimian
Sep 28, 2004·Annals of Hematology·K H WuC T Peng
Mar 21, 2008·Annals of Hematology·Amal El-BeshlawyAli Taher
Dec 2, 2010·The Korean Journal of Hematology·Sung Chul WonChuhl Joo Lyu
Dec 18, 2007·European Journal of Haematology·Athanassios AessoposMaria Tsironi
Dec 13, 2005·Annals of the New York Academy of Sciences·A PigaF Longo
Dec 6, 2005·Molecular and Cellular Biochemistry·Ying Liu, Douglas M Templeton
Aug 24, 2013·The Cochrane Database of Systematic Reviews·Sheila A FisherDavid J Roberts
Oct 29, 2009·International Journal of Hematology·Vip ViprakasitArchrob Khuhapinant
Oct 9, 2007·The Biochemical Journal·Lakshmi D DevanurRobert C Hider
Jun 10, 2021·ACS Chemical Biology·Usama AbbasiJayachandran N Kizhakkedathu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.